Effect of ciprofibrate on fibrinogen synthesis in vitro on hepatoma cells and in vivo in genetically obese Zucker rats

Blood Coagulation and Fibrinolysis

Volumn 10, Issue 5, 1999, Pages 239-244

  Herbert, J M ^a   Bernat, A ^a   Chatenet Duchene L ^a  

^a SANOFI   (France)

Author keywords

Ciprofibrate; Fibrinogen; HepG2; Obese; Zucker

Indexed keywords

ANTILIPEMIC AGENT; BEZAFIBRATE; CIPROFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FIBRINOGEN; INTERLEUKIN 6; MESSENGER RNA; ONCOSTATIN M; PROTEIN SUBUNIT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULANT THERAPY; ARTICLE; BETA CHAIN; CELL STRAIN HEPG2; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; FIBRINOGEN SYNTHESIS; HUMAN; HUMAN CELL; MALE; NONHUMAN; OBESITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; VEIN THROMBOSIS; VENOUS STASIS;

EID: 0032807323     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199907000-00004     Document Type: Article

References (18)

1. 1. Wilhemsen L, Svardsudd K, Korgan-Bengsten K, Larsson B, Welin L, Tibblin C. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-505.
2. 2. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WRS, et al. Haemostatic function and ischemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; ii: 533-537.
3. 3. Kanell WB, Wolf PA, Castelli WP, D'Argostino RB. Fibrinogen and risk of cardiovascular disease. JAMA 1987; 258: 1183-1186.
4. 4. Illingworth DR, Olsen GD, Cook SF, Sexton GJ, Wendel HA, Connor WE. Ciprofibrate in the therapy of type II hypercholesterolemia - a double-blind trial. Atherosclerosis 1982; 44: 211-221.
5. 5. Krockx M, de Maat MPM, Knipscheer HC, Kastelein JJP, Kluft C, Princen HMG, et al. Effect of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasmmogen activator inhibitor-1 and fibrinogen in hyperlipidaemic patients. Thromb Haemost 1997; 78: 1167-1172.
6. 6. de Maat MPM, Knipscheer HC, Kastelein JJP, Kluft C. Modulation of plasma fibrinogen levels by ciprofibrate and gemfibrozil in primary hyperlipidemia. Thromb Haemost 1997; 77: 75-79.
7. 7. Staels B, Koenig W, Habib A, Merval R, Lebret M, Delerive P, et al. Activation of human aortic smooth-muscle cells is inhibited by PPARa but not by PPARg activators. Nature 1998; 393: 790-793.
8. 8. Kushner I. The phenomenon of the acute phase response. Ann NY Acad Sci 1982; 389: 39-48.
9. 9. Baumann H, Onorato V, Gauldie J, Jahreis GP. Distinct sets of acute phase plasma proteins are stimulated by separate human hepatocyte-stimulating factors in monokines in rat hepatoma cells. J Biol Chem 1987; 262: 9756-9768.
10. 10. Pickart L. Suppression of acute-phase synthesis of fibrinogen by a hypolipemic drug (clofibrate). Int J Tiss React 1981; 3: 65-72.
11. 11. Vasse M, Collet JP, Soria J, Mirshahi SS, Vannier JP, Soria C. Fibrinogen, a vascular risk factor: a simple marker or a real cause of vascular lesion? Thromb Haemost 1994; 75: 349-352.
12. 12. Vasse M, Paysant J, Soria J, Mirshahi SS, Vannier JP, Soria C. Down-regulation of fibrinogen biosynthesis by IL-4, IL-10 and IL-13. Br J Haematol 1996; 93: 955-961.
13. 13. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanatephenol-chloroform extraction. Ann Biochem 1987; 162: 156-159.
14. 14. Herbert JM, Hérault JP, Bernat A, Van Amsterdam RGM, Vogel GMT, Lormeau JC, et al. Biochemical and pharmacological properties of Sanorg32701 -comparison with the "synthetic pentasaccharide" (SR90107/Org31540) and standard heparin. Circ Res 1996; 79: 590-600.
15. 15. Simpson IA, Lorimer AR, Walker ID. Davidson JF. Effect of ciprofibrate on platelet aggregation and fibrinolysis in patients with hypercholesterolemia. Thromb Haemost 1985; 54: 442-444.
16. 16. Pacot C, Petit M, Caira F, Rollin M, Althoff J, Zahnd JP, et al. Response of genetically obese Zucker rats to ciprofibrate, a hypolipidemic agent, with peroxisome proliferation activity as compared to Zucker lean and Sprague-Dawley rats. Biol Cell 1993; 77: 27-35.
17. 17. de Maat MPM, Arnold AER, van Buren S, Wilson JHP, Kluft C. Modulation of plasma fibrinogen levels by ticlopidine in healthy volunteers and patients with stable angina pectoris. Thromb Haemost 1996; 76: 166-170.
18. 18. Vu-Dac N, Schoonjans K, Laine B, Fruchart JC, Auwerx J, Staels B. Negative regulation of the human apolipoprotein A-1 promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. J Biol Chem 1994; 269: 31012-31018.